16.11.2016
B.R.A.I.N. Biotechnology Research And Information Network AG DE0005203947
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG: Two major food categories have joined DOLCE
DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG /
Key word(s): Miscellaneous/Alliance
B.R.A.I.N. Biotechnology Research And Information Network AG: Two major food
categories have joined DOLCE
16.11.2016 / 08:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Two major food categories have joined DOLCE
Zwingenberg, Potsdam (Germany) and Lestrem (France), November 16, 2016: The
bioeconomy company BRAIN AG (ISIN DE0005203947 / WKN 520394), the natural
product specialist AnalytiCon Discovery GmbH and Roquette, a global leader
in specialty food ingredients from plant-based raw materials, announced
today that two major food categories have already joined the recently
published strategic DOLCE partnership. This newly created partnership was
started in August 2016 and offers consumer product goods companies a
platform providing expert know-how to develop and produce natural
sweetening solutions in order to achieve sugar- and calorie reduction in
diverse food and beverage categories.
The three DOLCE research partners together have been in discussions with
many of the global Fortune 500 consumer product goods companies ("CPGCs")
representing the largest food and beverage brands.
Already two food categories, namely "morning foods" and "snacks", have
joined the program and committed to DOLCE. The interest of such CPGC
members is to integrate newly developed, innovative, and all natural DOLCE
sweet solutions into their end products to address the critical need for
sugar reduction in the global nutrition market. Further financial details
are not disclosed.
With the recent win of two global food categories, the DOLCE initiative
proves that it can cover the complete value chain from the discovery &
development (BRAIN and AnalytiCon) over the formulation & production
(Roquette) to the marketing & sales (CPGCs) of novel, natural sweet
solutions for expanded food and beverage segments. Further CPGCs are
invited to join the DOLCE Program as members in selected application
fields.
According to a study of Lux Research from January 2016, sugar substitutes
today account for 22% of the total sweetener market, yet natural sweetener
alternatives represent only 1%. Along with trends towards natural and
healthy ingredients, these natural alternatives have the potential to
replace between 2% and 25% of total sucrose across product categories like
bakery and cereal, beverage, and confection.
+++ENDS+++
About BRAIN
BRAIN is one of Europe's leading technology companies in the field of
industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN
identifies previously untapped, efficient enzymes, microbial producer
organisms or natural substances from complex biological systems that can be
put to industrial use. The innovative solutions and products developed by
help of this "Toolbox of Nature" are successfully applied in the chemistry,
the cosmetics and the food industries. Today, BRAIN's business model is
based on two pillars - "BioScience" and "BioIndustrial". The first pillar,
"BioScience", comprises its - frequently exclusive - collaboration business
with industrial partners. The second pillar "BioIndustrial" comprises the
development and commercialisation of BRAIN's own products and active
product components. Further information is available at www.brain-
biotech.de/en
Contact:
B.R.A.I.N
Biotechnology Research And Information Network AG
Dr. Martin Langer
Executive Vice President
Corporate Development
Darmstädter Str. 34-36
64673 Zwingenberg, Germany
Tel.: +49-6251-9331-0
Fax: +49-6251-9331-11
E-Mail: [email protected]
www.brain-biotech.de
Disclaimer
This press release contains forward-looking statements. These statements
reflect the current views, expectations, and assumptions of the management
of BRAIN AG and are based on information currently available to the
management. Forward-looking statements are not guarantees of future
performance and involve known and unknown risks and uncertainties that
could cause actual results, performance or events to differ materially from
those expressed or implied in such statements. There are numerous factors
which could influence the future performance by and future developments at
BRAIN AG and the BRAIN group of companies. Such factors include, but are
not limited to, changes in the general economic and competitive
environment, risks associated with capital markets, currency exchange rate
fluctuations, changes in international and national laws and regulations,
in particular with respect to tax laws and regulations, and other factors.
BRAIN AG does not undertake any obligation to update or revise any forward-
looking statements.
---------------------------------------------------------------------------
16.11.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: B.R.A.I.N. Biotechnology Research And Information Network
AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.de
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
521179 16.11.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
B.R.A.I.N. Biotechnology Research And Information Network AG ISIN: DE0005203947 können Sie bei EQS abrufen
Biotechnologie , 520394 , BNN , XETR:BNN